Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Is Arrowhead Pharmaceuticals Stock a Buy or Sell After the CEO Sold Shares Worth $5.4 Million?
CEO Christopher Anzalone sold 85,000 shares in the open market on Dec. 17, 2025, for a transaction value of ~$5,443,462. This sale represented 2.17% of Mr.
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment Approaches Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment Approaches Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at TD Cowen Treatment Advancements in Obesity and Related Disorders Summit Transcript
Arrowhead Pharmaceuticals, Inc. ( ARWR ) TD Cowen Treatment Advancements in Obesity and Related Disorders Summit November 24, 2025 1:30 PM EST Company Participants James Hamilton - Chief Medical Officer and Head of R&D Conference Call Participants Joseph Thome - TD Cowen, Research Division Presentation Joseph Thome TD Cowen, Research Division Everyone, and thank you for joining us at TD Cowen's 2025 Treatment Advances in Obesity Summit. I'm Joe Thome, one of the senior biotech analysts here on the team at TD Cowen.
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2025 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. ( ARWR ) Q4 2025 Earnings Call November 25, 2025 4:30 PM EST Company Participants Vincent Anzalone - Head of Investor Relations & VP Dr. Christopher Anzalone - Chairman, CEO & President Bruce Given - Chief Medical Scientist Andy Davis - SVP of Cardiovascular & Head of Metabolic Franchise James Hamilton - Chief Medical Officer and Head of R&D Daniel Apel - Chief Financial Officer Conference Call Participants Luca Issi - RBC Capital Markets, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Maurice Raycroft - Jefferies LLC, Research Division Dina Ramadane - BofA Securities, Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Mani Foroohar - Leerink Partners LLC, Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Andrea Tan - Goldman Sachs Group, Inc., Research Division Michael Ulz - Morgan Stanley, Research Division Madison Wynne El-Saadi - B.
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome Transcript
Arrowhead Pharmaceuticals, Inc. ( ARWR ) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome November 18, 2025 1:30 PM EST Company Participants Vincent Anzalone - Head of Investor Relations & VP Dr. Christopher Anzalone - Chairman, CEO & President James Hamilton - Chief Medical Officer and Head of R&D Bruce Given - Chief Medical Scientist Andy Davis - SVP of Cardiovascular & Head of Metabolic Franchise Bruce Given Conference Call Participants Ryan Mcelroy - Leerink Partners LLC, Research Division Morgan Lamberti - Goldman Sachs Group, Inc., Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Farzin Haque - Jefferies LLC, Research Division Luca Issi - RBC Capital Markets, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Avraham Novick - Morgan Stanley, Research Division Chi Meng Fong - BofA Securities, Research Division John Peyton Bohnsack - TD Cowen, Research Division Madison Wynne El-Saadi - B. Riley Securities, Inc., Research Division William Pickering - Sanford C.
Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead
A busy period is ahead for Arrowhead Pharmaceuticals on regulatory, legal, and clinical fronts. The PDUFA date with the FDA for plozasiran is tomorrow, and an approval should be expected, but competitor Ionis is suing for infringement of its '333 patent. Ionis' olezarsen recently generated very strong phase 3 results in severe hypertriglyceridemia patients and these results offer positive read-through for plozasiran's phase 3 trial with data in mid-2026.
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 11:30 AM EDT Company Participants Dr. Christopher Anzalone - Chairman, CEO & President James Hamilton - Chief Medical Officer and Head of R&D Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good afternoon, everyone.
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Cantor Global Healthcare Conference 2025 Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Cantor Global Healthcare Conference 2025 September 4, 2025 9:10 AM EDT Company Participants Dr. Christopher Anzalone - Chairman, CEO & President Conference Call Participants Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Presentation Prakhar Agrawal Senior Biotech Analyst All right. Welcome, everyone.
Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place
Arrowhead stock is a Strong Buy due to significant pipeline progress, especially the upcoming FDA PDUFA review date of plozasiran for familial chylomicronemia syndrome. The PALISADE phase 3 trial for plozasiran showed robust efficacy in reducing triglycerides and acute pancreatitis risk, leading to an FDA PDUFA review date of November 18, 2025. Ongoing late-stage studies for severe hypertriglyceridemia (SHTG) and a lucrative Novartis partnership for ARO-SNCA further strengthen company's long-term growth prospects.
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q3 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Andy Davis - SVP of Cardiovascular & Head of Metabolic Franchise Bruce D. Given - Corporate Participant Chief Medical Scientist - Corporate Participant Christopher R.
